Related Experiment Videos
Insights
Bronchiolitis, a common viral infection in young children caused by respiratory syncytial virus (RSV), primarily requires oxygen and fluid therapy. Evidence for other drug therapies remains limited, highlighting the need for further research.
Area of Science:
- Pediatrics
- Infectious Diseases
- Pulmonology
Background:
- Bronchiolitis is a common lower respiratory tract infection in infants and young children.
- Respiratory syncytial virus (RSV) is the most frequent cause.
- It affects 6-10% of children under two years old, presenting with symptoms from mild wheezing to severe respiratory distress.
Purpose of the Study:
- To critically evaluate available studies on therapeutic approaches for bronchiolitis.
- To assess the efficacy of various treatments, including drug therapies.
- To provide insights into the management, prognosis, and prevention of this condition.
Main Methods:
- Review and critical evaluation of existing scientific literature on bronchiolitis.
- Analysis of studies investigating different therapeutic interventions.
- Assessment of data on incidence, etiology, epidemiology, clinical presentation, and prevention.
Main Results:
- Oxygen and fluid therapy are the cornerstones of management for hospitalized infants with hypoxemia and to prevent dehydration.
- Limited data support the efficacy of adrenergic drugs, theophylline, and corticosteroids; most studies show no benefit.
- Ribavirin may reduce viral shedding, and antibiotics are only indicated for secondary bacterial infections.
Conclusions:
- Oxygen and fluid therapy are essential in managing bronchiolitis.
- Current evidence for pharmacological interventions beyond supportive care is largely lacking.
- Further research is needed to establish specific guidelines for drug use in bronchiolitis treatment.
Abstract:
The incidence, etiology, epidemiology, clinical presentation, treatment, prognosis, and prevention of bronchiolitis are discussed with a critical evaluation of the available studies on various therapeutic approaches. Bronchiolitis is a lower respiratory-tract viral infection that affects 6-10% of all children below two years of age. Respiratory syncytial virus (RSV) is the usual pathogen. The symptoms range from mild wheezing to severe respiratory distress. An infected child usually has a fever, a rapid pulse, an increased breathing rate, and difficulty in breathing. Because most of the infants hospitalized with bronchiolitis have hypoxemia, the administration of oxygen is the mainstay of therapy. Correct fluid therapy is essential to avoid dehydration and overhydration. Limited data are available on the use of drugs in the management of bronchiolitis. Although a variety of adrenergic drugs, theophylline, and corticosteroids are used, sound efficacy data are lacking, and most studies have documented a lack of therapeutic benefits. One study reported that the combined use of corticosteroids and albuterol may be beneficial in severely ill patients. Recent studies have shown that the continuous administration of ribavirin may decrease viral shedding. Antibiotics are not indicated unless a secondary bacterial infection is present. Oxygen and fluid therapy have a clear role in the management of patients with bronchiolitis; however, no specific guidelines are available for the use of drugs in the treatment of these patients.